JOURNAL BROWSE
Search
Advanced SearchSearch Tips
S100A16 is a Prognostic Marker for Lung Adenocarcinomas
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
S100A16 is a Prognostic Marker for Lung Adenocarcinomas
Saito, Keita; Kobayashi, Makoto; Nagashio, Ryo; Ryuge, Shinichiro; Katono, Ken; Nakashima, Hiroyasu; Tsuchiya, Benio; Jiang, Shi-Xu; Saegusa, Makoto; Satoh, Yukitoshi; Masuda, Noriyuki; Sato, Yuichi;
  PDF(new window)
 Abstract
Background: Many functional molecules controlling diverse cellular function are included in low-molecular weight proteins and peptides. Materials and Methods: To identify proteins controlling function in lung adenocarcinomas (AC), we performed two-dimensional gel electrophoresis employing tricine-SDS polyacrylamide in the second dimension (tricine 2-DE). This system was able to detect proteins under 1 kDa even with post-translational modifications. To confirm the utility of detected proteins as novel tumor markers for AC, we performed immunohistochemical analysis using 170 formalin-fixed and paraffin-embedded lung AC tissues. Results: Tricine 2-DE revealed that five proteins including S100A16 were overexpressed in lung AC-derived cells compared with lung squamous cell carcinoma, small cell carcinoma, and large cell neuroendocrine carcinoma-derived cells. Immunohistochemically, S100A16 showed various subcellular localization in lung cancer tissues and a membranous staining status was correlated with the T-factor (P
 Keywords
Lung cancer;adenocarcinoma;S100A16;tricine-2DE;tumor marker;
 Language
English
 Cited by
1.
A pathology atlas of the human cancer transcriptome, Science, 2017, 357, 6352, eaan2507  crossref(new windwow)
2.
S100A16 is a prognostic marker for colorectal cancer, Journal of Surgical Oncology, 2017, 00224790  crossref(new windwow)
 References
1.
Chen H, Xu C, Jin Q, et al (2014). S100 protein family in human cancer. Am J Cancer Res, 4, 89-115.

2.
Diamandis EP (2006). Peptidomics for cancer diagnosis: present and future. J Proteome Res, 5, 2079-82. crossref(new window)

3.
Dong Q, Yan X, Kilpatrick LE, et al (2014). Tandem mass spectral libraries of peptides in digests of individual proteins: Human Serum Albumin (HSA). Mol Cell Proteomics, 13, 2435-49. crossref(new window)

4.
Goldstraw P, Crowley J, Chansky K, et al (2007). The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2, 706-14. crossref(new window)

5.
Gross SR, Sin CG, Barraclough R, et al (2014). Joining S100 proteins and migration: for better or for worse, in sickness and in health. Cell Mol Life Sci, 71, 1551-79. crossref(new window)

6.
He K, Wen XY, Li AL, et al (2013). Serum peptidome variations in a healthy population: reference to identify cancer-specific peptides. PLoS One, 8, 63724. crossref(new window)

7.
Hernandez JL, Padilla L, Dakhel S, et al (2013). Therapeutic targeting of tumor growth and angiogenesis with a novel anti-S100A4 monoclonal antibody. PLoS One, 8, 72480. crossref(new window)

8.
Jiang SX, Kameya T, Asamura H, et al (2004). hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod Pathol, 17, 222-9. crossref(new window)

9.
Jin Q, Chen H, Luo A, et al (2011). S100A14 stimulates cell proliferation and induces cell apoptosis at different concentrations via receptor for advanced glycation end products (RAGE). PLoS One, 6, 19375. crossref(new window)

10.
Kobayashi M, Nagashio R, Ryuge S, et al (2014). Acquisition of useful sero-diagnostic autoantibodies using the same patients’ sera and tumor tissues. Biomed Res, 35, 133-43. crossref(new window)

11.
Liu Y, Zhang R, Xin J, et al (2011). Identification of S100A16 as a novel adipogenesis promoting factor in 3T3-L1 cells. Endocrinol, 152, 903-11. crossref(new window)

12.
Marenholz I, Heizmann CW (2004). S100A16, a ubiquitously expressed EF-hand protein which is up-regulated in tumors. Biochemical Bioph Res Commun, 313, 237-44. crossref(new window)

13.
Nagashio R, Sato Y, Jiang SX, et al (2008). Detection of tumorspecific autoantibodies in sera of patients with lung cancer. Lung Cancer, 62, 364-73. crossref(new window)

14.
Sapkota D, Costea DE, Ibrahim SO, et al (2013). S100A14 interacts with S100A16 and regulates its expression in human cancer cells. PLoS One, 8, 76058. crossref(new window)

15.
Schmitt T, Ogris C, Sonnhammer EL (2014). FunCoup 3.0: database of genome-wide functional coupling networks. Nucleic Acids Res, 42, 380-8. crossref(new window)

16.
Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. crossref(new window)

17.
Tan HT, Low J, Lim SG, et al (2009). Serum autoantibodies as biomarkers for early cancer detection. FEBS J, 276, 6880-904. crossref(new window)

18.
Tanaka M, Ichikawa-Tomikawa N, Shishito N, et al (2015). Co-expression of S100A14 and S100A16 correlates with a poor prognosis in human breast cancer and promotes cancer cell invasion. BMC Cancer, 15, 53. crossref(new window)

19.
Travis WD CT, Corrin B, Shimosato EY (1999). World Health Organization Inter-national histological classification of tumors; histological typing of lung and pleural tumors. Springer.

20.
Zhao CB, Bao JM, Lu YJ, et al (2014). Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer. Am J Cancer Res, 4, 369-77.

21.
Zhou W, Pan H, Xia T, et al (2014). Up-regulation of S100A16 expression promotes epithelial-mesenchymal transition via Notch1 pathway in breast cancer. J Biomed Sci, 21, 97. crossref(new window)